Rekah Pharmaceutical Industry Ltd.

Tel Aviv Stock Exchange REKA.TA

Rekah Pharmaceutical Industry Ltd. Operating Income for the year ending December 31, 2023: USD 800.34 K

Rekah Pharmaceutical Industry Ltd. Operating Income is USD 800.34 K for the year ending December 31, 2023, a -78.75% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Rekah Pharmaceutical Industry Ltd. Operating Income for the year ending December 31, 2022 was USD 3.77 M, a -17.26% change year over year.
Rekah Pharmaceutical Industry Ltd. Operating Income for the year ending December 31, 2021 was USD 4.55 M, a -30.04% change year over year.
Rekah Pharmaceutical Industry Ltd. Operating Income for the year ending December 31, 2020 was USD 6.51 M, a 95.25% change year over year.
Rekah Pharmaceutical Industry Ltd. Operating Income for the year ending December 31, 2019 was USD 3.33 M, a -12.27% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Tel Aviv Stock Exchange: REKA.TA

Rekah Pharmaceutical Industry Ltd.

CEO	Mr. Mordechai Elgrabli
IPO Date	Aug. 12, 2002
Location	Israel
Headquarters	30 Hamelach Street
Employees	427
Sector	Health Care
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies

Description

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.

Key trends

Past 5 years